NeuroKaire key facts
- Operator of a medical platform intended to transform brain health and eliminate suffering precision medicine in psychiatry and neurology.
- It has raised $21.2M; the latest was Later Stage VC ($10.0M) in May 2024.
- Notable investors include MassChallenge, Innovation Authority, Howard Morgan, BioGiv Excubator, Calcalist — 12 tracked in total.
- Status: Privately Held (backing).
Who backs NeuroKaire
12+- ·The complete investor list: 12 names
- ·Watch NeuroKaire: the Monday email on marks, rounds and moves
NeuroKaire funding rounds
No funding rounds for NeuroKaire are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
NeuroKaire investors
12 investors are on record for NeuroKaire, including MassChallenge, Innovation Authority, Howard Morgan and BioGiv Excubator.
About NeuroKaire
Operator of a medical platform intended to transform brain health and eliminate suffering precision medicine in psychiatry and neurology. The company's innovative technology also provides pharmaceutical companies with essential tools for targeted drug discovery and development, enabling clinicians to identify the optimal antidepressant based on the unique response of a patient's brain cells combined with their genetics and medical history.
- Sector
- Healthcare
- HQ
- Kearny, NJ, United States
- Founded
- 2018
- Employees
- 44
- Website
- neurokaire.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
NeuroKaire doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.